Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab by Theodore-Oklota C, Humphrey L, Wiesner C, Schnetzler G, Hudgens S, Campbell A

Get full text

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Contro... by Portale, A, Carpenter, T, Brandi, M, Briot, K, Cheong, H, Cohen-Solal, M, Crowley, R, Jan De Beur, S, Eastell, R, Imanishi, Y, Imel, E, Ing, S, Ito, N, Javaid, M, Kamenicky, P, Keen, R, Kubota, T, Lachmann, R, Perwad, F, Pitukcheewanont, P, Ralston, S, Takeuchi, Y, Tanaka, H, Weber, T, Yoo, H, Zhang, L, Theodore-Oklota, C, Mealiffe, M, San Martin, J, Insogna, K